



Unione Europea  
FESR



Repubblica Italiana

# PREFER

Sviluppo di un prodotto biocompatibile per la terapia delle ferite difficili




UNIVERSITÀ  
DEGLI STUDI DI TRIESTE



OBJECTIVE. TO BRING TO TRL 6 – READY FOR TRIALS IN HUMAN – AN ATMP THAT HAS SHOWN EFFICACY IN THERAPEUTIC REVASCULARIZATION (IN VIVO MODELS)

Treat  
Difficult to  
Heal Wounds



© Healthwise, Incorporated

1. EXTRACELLULAR MATRIX
2. ENDOTHELIAL CELLS, EXPANDED IN AUTOMATED BIOREACTOR
3. GROWTH FACTORS TO STIMULATE VESSEL FORMATION AND SKIN EPITHELIAL RE-GROWTH
4. ATMP MANUFACTURING

Budget 1.102.085 EUR

- A. RESEARCH – ICGEB / UNITS
- B. LEAD USER – UNITS
- C. ATMP MANUFACTURING – VIVABIOCELL
- D. CRO – ZETA RESEARCH